Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023)

SAB Biotherapeutics (SABS) has disclosed Change in Receivables for 3 consecutive years, with -$361735.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Receivables fell 110.86% year-over-year to -$361735.0, compared with a TTM value of -$5.6 million through Dec 2023, down 126.42%, and an annual FY2023 reading of -$5.6 million, down 126.42% over the prior year.
  • Change in Receivables was -$361735.0 for Q3 2023 at SAB Biotherapeutics, up from -$401388.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.5 million in Q2 2021 and bottomed at -$9.0 million in Q1 2021.
  • Average Change in Receivables over 3 years is -$1.9 million, with a median of -$2.2 million recorded in 2022.
  • Peak annual rise in Change in Receivables hit 148.28% in 2022, while the deepest fall reached 235.32% in 2022.
  • Year by year, Change in Receivables stood at -$2.2 million in 2021, then tumbled by 235.32% to -$7.4 million in 2022, then skyrocketed by 95.1% to -$361735.0 in 2023.
  • Business Quant data shows Change in Receivables for SABS at -$361735.0 in Q3 2023, -$401388.0 in Q2 2023, and -$4.8 million in Q1 2023.